DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Pravastatin Sodium is a drug marketed by Accord Hlthcare, Apnar Pharma Lp, Apotex, Aurobindo Pharma Ltd, Biocon Pharma, Cipla, Dr Reddys Labs Inc, Glenmark Generics, Hisun Pharm Hangzhou, Lupin Pharms, Mylan, Mylan Pharms Inc, Pliva Hrvatska Doo, Ranbaxy Labs Ltd, Teva, Teva Pharms, Watson Labs, and Zydus Pharms Usa. and is included in eighteen NDAs.
The generic ingredient in PRAVASTATIN SODIUM is pravastatin sodium. There are sixteen drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the pravastatin sodium profile page.
A generic version of PRAVASTATIN SODIUM was approved as pravastatin sodium by TEVA on April 24th, 2006.
Summary for PRAVASTATIN SODIUM
Recent Clinical Trials for PRAVASTATIN SODIUM
Identify potential brand extensions & 505(b)(2) entrants
|University of Maryland, Baltimore||Phase 4|
|University of Thessaly||N/A|
|University of Southern California||Phase 2|